Some of the proteins identified in this study such as CD276 are already under investigation, both pre-clinically (101, 102) and in humans, with recent studies showing the clinical administration of CD276 (B7-H3)–targeted CAR T cells to treat patients with GBM (103) and an on ongoing phase I clinical trial (21). Here, CD276 is linked to glioblastoma.